Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 49Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Burkitt Lymphoma 12Lymphoma, Mantle-Cell 6Recurrence 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Leukemia 4Immunoglobulin Light-chain Amyloidosis 4Breast Neoplasms 4Blast Crisis 4Vomiting 3Smoldering Multiple Myeloma 3Myelodysplastic Syndromes 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Nausea 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × POEMS Syndrome × dexamethasone 21-phosphate × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡